Treatment Strategies for Nonobstructive Heart Disease

For many years, patients with “clear” arteries were often sent home with no treatment plan. We now know that treating non-obstructive heart disease requires a precise, personalized approach. Research, such as the CorMicA trial, supports the idea that when doctors tailor treatment to a patient’s specific “endotype” (their unique subtype of disease), patients often experience significant improvements in their chest pain and overall quality of life ^[1][2].

Treatment is not “one-size-fits-all.” Instead, it is divided into two parts: building a healthy foundation for your blood vessels and then adding specific medications to stop the pain ^[3][4].

Foundational Care: Protecting the Vessel Lining

The first goal is to stabilize the endothelium (the lining of your arteries) and reduce the risk of future events ^[3]. These choices depend heavily on your individual cardiovascular risk, plaque burden, blood pressure, and kidney function.

• Statins: These may be used for cholesterol, and to help the artery lining heal and stay flexible ^[5][6].
• ACE Inhibitors or ARBs: These blood pressure medications help the vessels relax and can improve the heart’s ability to increase blood flow during stress ^[3][7]. They are often considered when managing overall ASCVD risk and blood pressure ^[5].
• Lifestyle & Rehab: Structured exercise, smoking cessation, and cardiac rehabilitation have been shown to improve endothelial function and reduce angina frequency in patients with INOCA ^[6].

Endotype-Guided Therapy: Stopping the Pain

Once the foundation is set, your doctor will choose “anti-anginal” medications based on whether your issue is a flow problem (microvascular) or a cramp problem (vasospasm).

For Microvascular Angina (CMD)

If your tiny vessels struggle to open or have high resistance, the goal is to improve flow ^[8].

• Beta-Blockers: These are often a choice for microvascular disease, as they slow the heart rate and give the tiny vessels more time to deliver oxygen-rich blood ^[3][8].
• Calcium Channel Blockers (CCBs): These may be added if beta-blockers aren’t enough, as they help the vessel walls relax ^[8].
• Ranolazine: This is a specialized medication for chronic chest pain. Evidence suggests it can improve quality of life specifically for some patients with microvascular dysfunction ^[9].

For Vasospastic Angina (VSA)

If your arteries are prone to sudden spasms or “cramping,” the strategy shifts toward preventing those contractions ^[10].

• Calcium Channel Blockers (CCBs): These are the cornerstone of treatment for spasms. They work by preventing the smooth muscle in the artery walls from tightening inappropriately ^[10][11].
• Nitrates:
  • Short-acting: These (like sublingual nitroglycerin) are essential for stopping an acute attack of chest pain ^[10].
  • Long-acting: While these are common for many heart patients, they are often less effective for microvascular disease and are used more selectively for those with frequent spasms ^[9][12].
• Important Safety Note: Beta-blockers can actually worsen symptoms in patients with confirmed vasospastic angina, which highlights why accurate diagnosis is critical.

Refining Your Regimen and Treating MINOCA

Because INOCA and MINOCA are complex, it is common to have a “mixed” endotype—where you have both a flow issue and a spasm issue ^[13]. In these cases, your doctor may prescribe a combination of medications. Any combination requires individualized cardiology supervision. For instance, combining a beta-blocker with certain rate-slowing calcium-channel blockers (like verapamil or diltiazem) can produce clinically important bradycardia, atrioventricular block, or hypotension.

If you have had a MINOCA event, therapy must be directed at the specific cause—such as plaque disruption, vasospasm, spontaneous coronary artery dissection (SCAD), embolism, or a nonischemic mimic like myocarditis—rather than treating all MINOCA as one uniform disease. Your treatment should be based on your actual test results, not a “wait and see” approach.